These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15841355)

  • 1. [Drug therapy for benign prostatic hyperplasia. Systematic overview].
    Berges R; Höfner K
    Urologe A; 2005 May; 44(5):505-12. PubMed ID: 15841355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy of benign prostatic hyperplasia. Is combination therapy with 5 alpha-reductase inhibitors and alpha-receptor blockers effective?].
    Horninger W; Bartsch G
    Urologe A; 2002 Sep; 41(5):442-6. PubMed ID: 12426860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia.
    Choi JD; Kim JH; Ahn SH
    Urol Int; 2016; 96(4):406-12. PubMed ID: 26824527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
    Spivak LG; Lokshin KL; Vinarov AZ
    Urologiia; 2015; (4):125-33. PubMed ID: 26665780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
    Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
    Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
    Perry R; Milligan G; Anderson P; Gillon A; White M
    Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R
    Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review.
    Andersen JT
    Drugs Aging; 1995 May; 6(5):388-96. PubMed ID: 7544174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.